Keyvan Rezai

Keyvan Rezai

Auto-generated profile, based on publicly available information

Keyvan Rezai

Institut Curie, Hôpital René Huguenin, Saint-Cloud, France

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in The Lancet Haematology
Verified
Journal Article
Closed access
SASandy Amorim
Sandy Amorim
ASAnastasios Stathis
Anastasios Stathis
MGMary Gleeson
Mary Gleeson
SISunil Iyengar
Sunil Iyengar
VMValeria Magarotto
Valeria Magarotto
CTCatherine Thieblemont
Catherine Thieblemont

1 April 2016 in The Lancet Haematology
Verified
Journal Article
Closed access
CBCéline Berthon
Céline Berthon
EREmmanuel Raffoux
Emmanuel Raffoux
XTXavier Thomas
Xavier Thomas
NVNorbert Vey
Norbert Vey
CGCarlos Gomez-Roca
Carlos Gomez-Roca
HDHervé Dombret
Hervé Dombret

20 October 2018 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JLJeremy Lewin
Jeremy Lewin
JSJean-Charles Soria
Jean-Charles Soria
ASAnastasios Stathis
Anastasios Stathis
JDJean-Pierre Delord
Jean-Pierre Delord
SPSolange Peters
Solange Peters
CMChristophe Massard
Christophe Massard
Purpose: Birabresib (MK-8628/OTX015) is a first-in-class bromodomain inhibitor with activity in select hematologic tumors. Safety, efficacy, and pharmacokinetics of birabresib were evaluated in patients with castrate-resistant prostate cancer, nuclear protein in testis midline carcinoma (NMC), and non–small-cell lung cancer in this phase Ib study. Patients and Methods: Forty-seven patients were enrolled to receive birabresib once daily at starting doses of 80 mg continuously (cohort A) or 100 mg for 7 consecutive days (cohort B) in 21-day cycles using a parallel dose escalation 3 + 3 design. The primary objective was occurrence of dose-limiting toxicities (DLTs) and determination of the recommended phase II dose. Results: Of 46 treated patients, 26 had castrate-resistant prostate cancer, 10 NMC, and 10 non–small-cell lung cancer. For cohort A, four of 19 (21%) evaluable patients had DLTs at 80 mg once daily (grade 3 thrombocytopenia [n = 3], ALT/hyperbilirubinemia [n = 1]) and two of three had DLTs at 100 mg once daily (grade 2 anorexia and nausea with treatment delay > 7 days [n = 1], grade 4 thrombocytopenia [n = 1]). No DLTs occurred in cohort B. Of 46 patients, 38 (83%) had treatment-related adverse events (diarrhea, 17 [37%]; nausea, 17 [37%]; anorexia, 14 [30%]; vomiting, 12 [26%]; thrombocytopenia 10 [22%]). Three patients with NMC (80 mg once daily) had a partial response (Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) with duration of 1.4 to 8.4 months. Pharmacokinetic analysis indicated a dose-proportional increase in birabresib exposure and rapid absorption. Conclusion: The recommended phase II dose of birabresib in patients with select solid tumors is 80 mg once daily with continuous dosing. Birabresib has dose-proportional exposure and a favorable safety profile, with clinical activity observed in NMC. Future studies of birabresib must consider intermittent scheduling to possibly mitigate the toxicities of chronic dosing.

7 July 2016 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
CBCaroline Berenguer‐Daizé
Caroline Berenguer‐Daizé
LALucile Astorgues‐Xerri
Lucile Astorgues‐Xerri
EOElodie Odore
Elodie Odore
MCMylène Cayol
Mylène Cayol
ECEsteban Cvitkovic
Esteban Cvitkovic
LOL'Houcine Ouafik
L'Houcine Ouafik
Bromodomain and extraterminal (BET) bromodomain (BRD) proteins are epigenetic readers that bind to acetylated lysine residues on chromatin, acting as co‐activators or co‐repressors of gene expression. BRD2 and BRD4, members of the BET family, are significantly increased in glioblastoma multiforme (GBM), the most common primary adult brain cancer. OTX015 (MK‐8628), a novel BRD2/3/4 inhibitor, is under evaluation in dose‐finding studies in solid tumors, including GBM. We investigated the pharmacologic characteristics of OTX015 as a single agent and combined with targeted therapy or conventional chemotherapies in glioblastoma cell lines. OTX015 displayed higher antiproliferative effects compared to its analog JQ1, with GI50 values of approximately 0.2 µM. In addition, C‐MYC and CDKN1A mRNA levels increased transiently after 4 h‐exposure to OTX015, while BRD2, SESN3, HEXIM‐1, HIST2H2BE, and HIST1H2BK were rapidly upregulated and sustained after 24 h. Studies in three additional GBM cell lines supported the antiproliferative effects of OTX015. In U87MG cells, OTX015 showed synergistic to additive activity when administered concomitant to or before SN38, temozolomide or everolimus. Single agent oral OTX015 significantly increased survival in mice bearing orthotopic or heterotopic U87MG xenografts. OTX015 combined simultaneously with temozolomide improved mice survival over either single agent. The passage of OTX015 across the blood–brain barrier was demonstrated with OTX015 tumor levels 7 to 15‐fold higher than in normal tissues, along with preferential binding of OTX015 to tumor tissue. The significant antitumor effects seen with OTX015 in GBM xenograft models highlight its therapeutic potential in GBM patients, alone or combined with conventional chemotherapies.

4 September 2015 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
EOElodie Odore
Elodie Odore
FLFrançois Lokiec
François Lokiec
ECEsteban Cvitkovic
Esteban Cvitkovic
MBMohamed Bekradda
Mohamed Bekradda
PHPatrice Herait
Patrice Herait
KRKeyvan Rezaï
Keyvan Rezaï

7 December 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
RVRamiro Vázquez
Ramiro Vázquez
MRMaría E. Riveiro
María E. Riveiro
LALucile Astorgues-Xerri
Lucile Astorgues-Xerri
EOElodie Odore
Elodie Odore
KRKeyvan Rezai
Keyvan Rezai
Maurizio D'IncalciMaurizio D'Incalci
Maurizio D'Incalci
The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus